Tag Archives: Novartis

Valganciclovir: IPAB remands matter back to the Controller: patent to remain revoked

30th January, 2014: The Intellectual Property Appellate Board (IPAB) set aside the Patent Controller’s decision to revoke the patent relating to valganciclovir on technical grounds and remanded it to the Controller for re-consideration. In a significant development for patient groups,

Lawyers Collective Response to Testimony of Mr. Roy F Waldron, Pfizer Inc.

Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property (IP) regime in India. On June 27, 2013 a hearing, ‘A tangle

Indian Patent Law TRIPS Compliant: Novartis judgment shows the way

While patients groups around the world have expressed joy over the Novartis decision of the Supreme Court of India, western Multi National Companies (MNCs) and their governments have expressed extreme displeasure over it. Some in the US have even urged

Analysing the Novartis Story

Vol – XLVIII No. 32, August 10, 2013 | Anand Grover A detailed account of the examination of Section 3(d) of the Indian Patents Act in the Supreme Court’s judgment on Novartis’s patent application for Glivec. Anand Grover (anandgrover@gmail.com) is a Senior

Why Novartis case will help innovation

The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board’s decision to deny patent protection to Novartis’s application

India’s patent case victory rattles Big Pharma

Will India, the world’s biggest provider of low-cost generic medicines, be the pariah or the pioneer of the pharmaceutical world? There is renewed focus on this thorny question in the wake of India’s Supreme Court’s dismissal of Swiss pharma giant

Novartis Ruling Reverberates Past India’s Borders

India’s Supreme Court says drug maker Novartis can’t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth

Attack on affordable medicines continues in EU-India trade negotiations

Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world  10 April, 2013, New Delhi­- Thousands of people living with HIV, cancer patient groups & public health activists rallied